{"prompt": "['2016N293064_01', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Office spirometry (centralized)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Home spirometry - (weekly)', 'X', 'Randomization', 'Dispense study medication', 'Dispense log pad and provide training', 'X', 'Dispense MDI sensors and provide training', 'Study Treatment', 'Study Treatment Compliance (ediary)', 'Collect IP', 'Collect MDI sensors', 'X', 'Collect log pad', 'AE review', 'SAE review', 'Concomitant medication review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Clinical Outcomes Assessments', 'COPD exacerbation review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Rescue medication Use', 'SGRQ-C', 'X', 'X', 'COPD Assessment Test (CAT)', 'Participant Global Impression of COPD', 'severity', 'Participant Impression of change in COPD', 'severity', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '10']['2016N293064_01', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Genetic, Pharmacokinetic and Biomarker Blood Collections', 'Blood sample for Genetics', 'Blood sample for CRP', 'Blood sample for exploratory biomarkers', 'a', 'Informed consent may be signed prior to screening visit in the case that any changes in medications are necessary', 'b', 'Agreeing to genetic sample consent is not required for study participation', 'C', 'Smoking status/history assessed at screening; smoking status re-checked at Visit 2', 'd', 'Includes substance usage, past and present medical conditions and family history of premature CV disease', 'e', 'Hepatitis B (HBsAg) and Hepatitis C (HepC antibody) testing is required. If testing otherwise performed within 3 months prior to the first dose of study treatment, testing at', 'screening is not required. Hepatitis C RNA testing is optional; however a confirmatory negative Hepatitis C RNA test must be obtained, to be able to enrol participants with', 'positive Hepatitis C antibody due to prior resolved disease.', 'f', \"Participant's clinical status should be reviewed\", 'The timing and number of planned study assessments, including safety and biomarker assessments may be altered during the course of the study based on newly available data to', 'ensure appropriate data collection. Any changes in the timing or addition of time points for any planned study assess must be documented and approved by the relevant study team', 'member and then archived in the sponsor and site study files, but will not constitute a protocol amendment. The IRB/IEC will be informed of any safety issues that require alteration of', 'the safety monitoring scheme or amendment of the ICF.', '11']\n\n###\n\n", "completion": "END"}